Literature DB >> 22138488

Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, China.

Y Hser1, J Du, J Li, M Zhao, Y J Chang, C Y Peng, E Evans.   

Abstract

BACKGROUND: This study aims to: (1) document the prevalence of hepatitis C virus (HCV) among methadone maintenance treatment (MMT) patients in Kunming and Shanghai; (2) examine risk factors for HCV by comparing those who tested positive with those who were negative and (3) examine if HCV serostatus is related to attitudes toward MMT.
METHODS: Using data collected from 306 patients admitted to MMT in 2009-2010 in Shanghai and Kunming, we compared HCV-positive and HCV-negative patients (based on clinical records) on their HCV knowledge and risk behaviors and attitudes toward MMT.
RESULTS: The HCV seropositive rate was 53.3% (51.3% in Shanghai and 55.5% in Kunming) and a majority of patients did not know their serostatus. Patients scored on average fewer than 6 correct out of the 20 items in the HCV knowledge questionnaire. Recent injection use and length of opiate use were strong predictors of HCV status, while no differences were found between HCV-positive and HCV-negative individuals in sexual risks or HCV knowledge. Both groups expressed similar views toward MMT.
CONCLUSION: The high HCV prevalence and the general lack of knowledge about HCV infection, transmission and treatment suggest the need to provide HCV education and health promotion programs among patients in MMT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138488      PMCID: PMC3285118          DOI: 10.1093/pubmed/fdr098

Source DB:  PubMed          Journal:  J Public Health (Oxf)        ISSN: 1741-3842            Impact factor:   2.341


  19 in total

1.  The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users.

Authors:  S Darke; W Hall; N Heather; J Ward; A Wodak
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

2.  Self-reported hepatitis C virus antibody status and risk behavior in young injectors.

Authors:  Holly Hagan; Jennifer Campbell; Hanne Thiede; Steffanie Strathdee; Lawrence Ouellet; Farzana Kapadia; Sharon Hudson; Richard S Garfein
Journal:  Public Health Rep       Date:  2006 Nov-Dec       Impact factor: 2.792

3.  Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.

Authors:  M D Stein; J Maksad; J Clarke
Journal:  Drug Alcohol Depend       Date:  2001-02-01       Impact factor: 4.492

Review 4.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

5.  Hepatitis C knowledge among staff in U.S. drug treatment programs.

Authors:  Shiela M Strauss; Janetta M Astone-Twerell; Corrine Munoz-Plaza; Don C Des Jarlais; Marya Gwadz; Holly Hagan; Andrew Osborne; Andrew Rosenblum
Journal:  J Drug Educ       Date:  2006

6.  Changes in attitude toward methadone.

Authors:  B S Brown; D R Jansen; G J Benn
Journal:  Arch Gen Psychiatry       Date:  1975-02

7.  Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China.

Authors:  Rebecca J Garten; Shenghan Lai; Jinbing Zhang; Wei Liu; Jie Chen; David Vlahov; Xiao-Fang Yu
Journal:  Int J Epidemiol       Date:  2004-02       Impact factor: 7.196

8.  Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities.

Authors:  Robert Heimer; Scott Clair; Lauretta E Grau; Ricky N Bluthenthal; Patricia A Marshall; Merrill Singer
Journal:  Addiction       Date:  2002-10       Impact factor: 6.526

9.  The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users.

Authors:  Carol F Kwiatkowski; Karen Fortuin Corsi; Robert E Booth
Journal:  Addiction       Date:  2002-10       Impact factor: 6.526

10.  Community-based survey of HCV and HIV coinfection in injection drug abusers in Sichuan Province of China.

Authors:  Yu-Hua Ruan; Kun-Xue Hong; Shi-Zhu Liu; Yi-Xin He; Feng Zhou; Guan-Ming Qin; Kang-Lin Chen; Hui Xing; Jian-Ping Chen; Yi-Ming Shao
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

View more
  6 in total

Review 1.  The globalization of addiction research: capacity-building mechanisms and selected examples.

Authors:  Richard A Rawson; George Woody; Thomas F Kresina; Steven Gust
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

Review 2.  A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan.

Authors:  Heather Bennett; Nathalie Waser; Karissa Johnston; Jia-Horng Kao; Young-Suk Lim; Zhong-Ping Duan; Youn-Jae Lee; Lai Wei; Chien-Jen Chen; William Sievert; Yong Yuan; Hong Li
Journal:  Hepatol Int       Date:  2015-06-13       Impact factor: 6.047

3.  Risk Factors of Hepatitis C Virus Infection in Drug Users From Eleven Methadone Maintenance Treatment Clinics in Xi'an, China.

Authors:  Wei Xiaoli; Wang Lirong; Wang Xueliang; Li Jinsong; Li Hengxin; Jia Wei
Journal:  Hepat Mon       Date:  2014-11-23       Impact factor: 0.660

4.  Baseline HCV Antibody Prevalence and Risk Factors among Drug Users in China's National Methadone Maintenance Treatment Program.

Authors:  Changhe Wang; Cynthia X Shi; Keming Rou; Yan Zhao; Xiaobin Cao; Wei Luo; Enwu Liu; Zunyou Wu
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

5.  Hepatitis C infection, related services, and barriers to HCV treatment among drug users in methadone maintenance treatment (MMT) clinics in Shanghai, China.

Authors:  Zhi-Bin Li; Lei Zhang; Jun Wang; Le-Ping Huang; Zhi-Rong Zhou; Yi-Ning Cao; Min Zhao; Jiang Du
Journal:  Harm Reduct J       Date:  2017-11-02

6.  Estimating the prevalence of hepatitis C among intravenous drug users in upper middle income countries: A systematic review and meta-analysis.

Authors:  Víctor Granados-García; Yvonne N Flores; Lizbeth I Díaz-Trejo; Lucia Méndez-Sánchez; Stephanie Liu; Guillermo Salinas-Escudero; Filiberto Toledano-Toledano; Jorge Salmerón
Journal:  PLoS One       Date:  2019-02-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.